Use of plozasiran, an APOC3 inhibiting therapy from Arrowhead Pharmaceuticals, was associated with least squares mean reductions in triglyceride levels by 74% at 24 weeks, according to the SHASTA-2 trial.

Presented as a late-breaker at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, the trial, which included more than 200 patients with severe hypertriglyceridemia, provides evidence supporting the initiation of pivotal trials for plozasiran, according to lead investigator Daniel Gaudet, MD, PhD.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/plozasiran-reduces-triglycerides-apoc3-in-phase-2b-shasta-2-trial